Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Inclusion Criteria: * Patients must be \>= 24 months and \< 21 years of age at the time of study enrollment * Patient must have AML with an IDH2 mutation identified from a peripheral blood or bone marrow sample at the time of diagnosis and/or relapsed/refractory disease * Patient must have bone marrow assessment (aspiration or biopsy) with \> 5% leukemic blasts by morphology and/or flow cytometry in at least one of the following clinical scenarios: * Second or greater relapse after chemotherapy or hematopoietic stem cell transplant (HSCT) * Refractory after \>= 2 attempts at induction therapy * Relapsed patients * Must not have received prior re-induction therapy for this relapse * Each block of chemotherapy (i.e., cytarabine, daunorubicin and etoposide \[ADE\], cytarabine and mitoxantrone \[MA\]) is a separate re-induction attempt * Donor lymphocyte infusion (DLI) is considered a re-induction attempt * Refractory patients * Each attempt at induction therapy may include up to two chemotherapy courses * Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life * Evaluation of cerebrospinal flu…